Cargando…
Efficacy of Grignard Pure to Inactivate Airborne Phage MS2, a Common SARS-CoV-2 Surrogate
[Image: see text] Grignard Pure (GP) is a unique and proprietary blend of triethylene glycol (TEG) and inert ingredients designed for continuous antimicrobial treatment of air. TEG has been designated as a ″Safer Chemical” by the US EPA. GP has already received approval from the US EPA under its Sec...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001433/ https://www.ncbi.nlm.nih.gov/pubmed/36853925 http://dx.doi.org/10.1021/acs.est.2c08632 |
_version_ | 1784904135216201728 |
---|---|
author | Desai, Grishma Ramachandran, Gurumurthy Goldman, Emanuel Esposito, William Galione, Antony Lal, Altaf Choueiri, Toni K. Fay, Andre Jordan, William Schaffner, Donald W. Caravanos, Jack Grignard, Etienne Mainelis, Gediminas |
author_facet | Desai, Grishma Ramachandran, Gurumurthy Goldman, Emanuel Esposito, William Galione, Antony Lal, Altaf Choueiri, Toni K. Fay, Andre Jordan, William Schaffner, Donald W. Caravanos, Jack Grignard, Etienne Mainelis, Gediminas |
author_sort | Desai, Grishma |
collection | PubMed |
description | [Image: see text] Grignard Pure (GP) is a unique and proprietary blend of triethylene glycol (TEG) and inert ingredients designed for continuous antimicrobial treatment of air. TEG has been designated as a ″Safer Chemical” by the US EPA. GP has already received approval from the US EPA under its Section 18 Public Health Emergency Exemption program for use in seven states. This study characterizes the efficacy of GP for inactivating MS2 bacteriophage—a nonenveloped virus widely used as a surrogate for SARS-CoV-2. Experiments measured the decrease in airborne viable MS2 concentration in the presence of different concentrations of GP from 60 to 90 min, accounting for both natural die-off and settling of MS2. Experiments were conducted both by introducing GP aerosol into air containing MS2 and by introducing airborne MS2 into air containing GP aerosol. GP is consistently able to rapidly reduce viable MS2 bacteriophage concentration by 2–3 logs at GP concentrations of 0.04–0.5 mg/m(3) (corresponding to TEG concentrations of 0.025 to 0.287 mg/m(3)). Related GP efficacy experiments by the US EPA, as well as GP (TEG) safety and toxicology, are also discussed. |
format | Online Article Text |
id | pubmed-10001433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-100014332023-03-10 Efficacy of Grignard Pure to Inactivate Airborne Phage MS2, a Common SARS-CoV-2 Surrogate Desai, Grishma Ramachandran, Gurumurthy Goldman, Emanuel Esposito, William Galione, Antony Lal, Altaf Choueiri, Toni K. Fay, Andre Jordan, William Schaffner, Donald W. Caravanos, Jack Grignard, Etienne Mainelis, Gediminas Environ Sci Technol [Image: see text] Grignard Pure (GP) is a unique and proprietary blend of triethylene glycol (TEG) and inert ingredients designed for continuous antimicrobial treatment of air. TEG has been designated as a ″Safer Chemical” by the US EPA. GP has already received approval from the US EPA under its Section 18 Public Health Emergency Exemption program for use in seven states. This study characterizes the efficacy of GP for inactivating MS2 bacteriophage—a nonenveloped virus widely used as a surrogate for SARS-CoV-2. Experiments measured the decrease in airborne viable MS2 concentration in the presence of different concentrations of GP from 60 to 90 min, accounting for both natural die-off and settling of MS2. Experiments were conducted both by introducing GP aerosol into air containing MS2 and by introducing airborne MS2 into air containing GP aerosol. GP is consistently able to rapidly reduce viable MS2 bacteriophage concentration by 2–3 logs at GP concentrations of 0.04–0.5 mg/m(3) (corresponding to TEG concentrations of 0.025 to 0.287 mg/m(3)). Related GP efficacy experiments by the US EPA, as well as GP (TEG) safety and toxicology, are also discussed. American Chemical Society 2023-02-28 /pmc/articles/PMC10001433/ /pubmed/36853925 http://dx.doi.org/10.1021/acs.est.2c08632 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Desai, Grishma Ramachandran, Gurumurthy Goldman, Emanuel Esposito, William Galione, Antony Lal, Altaf Choueiri, Toni K. Fay, Andre Jordan, William Schaffner, Donald W. Caravanos, Jack Grignard, Etienne Mainelis, Gediminas Efficacy of Grignard Pure to Inactivate Airborne Phage MS2, a Common SARS-CoV-2 Surrogate |
title | Efficacy of Grignard
Pure to Inactivate Airborne Phage
MS2, a Common SARS-CoV-2 Surrogate |
title_full | Efficacy of Grignard
Pure to Inactivate Airborne Phage
MS2, a Common SARS-CoV-2 Surrogate |
title_fullStr | Efficacy of Grignard
Pure to Inactivate Airborne Phage
MS2, a Common SARS-CoV-2 Surrogate |
title_full_unstemmed | Efficacy of Grignard
Pure to Inactivate Airborne Phage
MS2, a Common SARS-CoV-2 Surrogate |
title_short | Efficacy of Grignard
Pure to Inactivate Airborne Phage
MS2, a Common SARS-CoV-2 Surrogate |
title_sort | efficacy of grignard
pure to inactivate airborne phage
ms2, a common sars-cov-2 surrogate |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001433/ https://www.ncbi.nlm.nih.gov/pubmed/36853925 http://dx.doi.org/10.1021/acs.est.2c08632 |
work_keys_str_mv | AT desaigrishma efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate AT ramachandrangurumurthy efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate AT goldmanemanuel efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate AT espositowilliam efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate AT galioneantony efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate AT lalaltaf efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate AT choueiritonik efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate AT fayandre efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate AT jordanwilliam efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate AT schaffnerdonaldw efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate AT caravanosjack efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate AT grignardetienne efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate AT mainelisgediminas efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate |